A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
收藏DataCite Commons2026-02-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008970/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The reason for this study is to compare the effect of the study drug tirzepatide to
semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last
approximately 47 weeks and may include about 12 visits.
提供机构：
Vivli
创建时间：
2023-05-26
